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A B S T R A C T
Increased permeability of the intestinal barrier is proposed as an underlying factor for obesity-associated
pathologies. Consumption of high fat diets (HFD) is associated with increased intestinal permeabilization and
increased paracellular transport of endotoxins which can promote steatosis and insulin resistance. This study
investigated whether dietary (-)-epicatechin (EC) supplementation can protect the intestinal barrier against HFD-
induced permeabilization and endotoxemia, and mitigate liver damage and insulin resistance. Mechanisms
leading to loss of integrity and function of the tight junction (TJ) were characterized. Consumption of a HFD for
15 weeks caused obesity, steatosis, and insulin resistance in male C57BL/6J mice. This was associated with
increased intestinal permeability, decreased expression of ileal TJ proteins, and endotoxemia. Supplementation
with EC (2–20 mg/kg body weight) mitigated all these adverse effects. EC acted modulating cell signals and the
gut hormone GLP-2, which are central to the regulation of intestinal permeability. Thus, EC prevented HFD-
induced ileum NOX1/NOX4 upregulation, protein oxidation, and the activation of the redox-sensitive NF-κB and
ERK1/2 pathways. Supporting NADPH oxidase as a target of EC actions, in Caco-2 cells EC and apocynin in-
hibited tumor necrosis alpha (TNFα)-induced NOX1/NOX4 overexpression, protein oxidation and monolayer
permeabilization. Together, our findings demonstrate protective effects of EC against HFD-induced increased
intestinal permeability and endotoxemia. This can in part underlie EC capacity to prevent steatosis and insulin
resistance occurring as a consequence of HFD consumption.
1. Introduction
Steatosis and insulin resistance are among the major and more se-
vere consequences of obesity. Nonalcoholic fatty liver disease (NAFLD)
is more frequent in individuals with diabetes, higher body mass index,
and those frequently consuming fast foods [1]. One of the hypotheses
on the mechanisms linking obesity and Western-style diets with NAFLD
and insulin resistance is the associated increase in intestinal perme-
ability [2,3]. In this regard, it is proposed that an increased transfer of
bacterial lipopolysaccharides (LPS) from the gut lumen into the
circulation can cause tissue inflammation and damage, which in the
liver would lead to steatosis and insulin resistance [3–5].
The intestinal barrier is composed of a single layer of intestinal
epithelial cells sealed by the tight junctions (TJs). TJs modulate in-
testinal permeability by regulating the paracellular transport of water
and ions. They also constitute the first line of defense against the entry
of noxious bacteria/bacterial toxins (e.g. lipopolysaccharide (LPS)) and
toxins/antigens present in food. Once transported via the paracellular
route, they can initiate local inflammation, and once in the circulation
they can also promote systemic tissue inflammation and damage [6–8].
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Increased intestinal permeability is observed in different pathologies
including celiac disease and inflammatory bowel diseases, and is pre-
sent in obesity and type 2 diabetes (T2D) [3,5,9,10]. Consumption of
high fat diets (HFD) also causes intestinal permeabilization, impairs
mucosal defenses [11], and alters the composition of the intestinal
microbiota [11]. In murine models, these intestinal alterations have
been attributed to the dietary fat per se [12], being present before the
development of obesity and insulin resistance [11].
(-)-Epicatechin (EC) is a flavan-3-ol abundant in human diet [13].
Cumulative evidence has shown an improvement of insulin sensitivity
in both humans and rodents upon consumption of EC or EC-containing
foods [14–19]. We previously observed that EC protects rodents from
dietary high fructose- and high fat-induced insulin resistance [18,19].
EC prevented the increased liver triglyceride deposition associated with
high fructose consumption in rats [18]. Although EC mitigates events
involved in hepatic and adipose tissue insulin resistance (i.e. NADPH
oxidase activation, oxidative stress, altered redox signaling, in-
flammation and endoplasmic reticulum stress) [18–21], the primary
mechanisms involved in EC protective effects remain unknown.
In vitro, EC mitigated the permeabilization of Caco-2 intestinal cell
monolayers induced by tumor necrosis factor alpha (TNFα) [22]. The
underlying protective mechanisms of EC involved the prevention of
TNFα-mediated NADPH oxidase activation, increased superoxide anion
production, and altered TJ protein expression and organization [22].
Given the above, we hypothesize that EC can mitigate HFD-induced
steatosis and insulin resistance by protecting the intestine from per-
meabilization. Thus, this study investigated the capacity of EC to pre-
vent liver fat deposition and inflammation in HFD-fed mice, and its
relationship to EC capacity to modulate intestinal permeability and the
associated endotoxemia. We characterized the effects of EC on major
events regulating intestinal permeability, including TJ protein expres-
sion, NADPH oxidases and modulatory redox sensitive signaling cas-
cades (NF-κB and extracellular signal-regulated kinase (ERK1/2)),
glucagon-like peptide-2 (GLP-2), and dysbiosis. The actions of EC on
NADPH oxidases NOX1 and NOX4, protein oxidation, and intestinal
permeability were further characterized in Caco-2 cell monolayers. EC
improved insulin sensitivity and mitigated the development of steatosis
in HFD-fed mice. This was associated with the prevention of HFD-in-
duced intestinal TJ disruption, permeabilization and endotoxemia. EC
protected TJs in part by preventing intestinal NOX1/NOX4 upregula-
tion, protein oxidation, and the activation of the redox-sensitive NF-κB
and ERK1/2 signaling cascades, and increasing plasma GLP-2. The
beneficial effects of EC at the gastrointestinal tract could in part un-
derlie its capacity to improve insulin sensitivity, steatosis, and other
obesity-associated pathologies.
2. Materials and methods
2.1. Materials
Cholesterol and triglycerides concentrations were determined using
kits purchased from Wiener Lab Group (Rosario, Argentina). Glucose
levels were measured using a kit purchased from Sigma-Aldrich Co (St.
Louis, MO). Concentrations of insulin, alanine transaminase (ALT),
GLP-2, and bile acids were determined using kits purchased from
Crystal Chem Inc (Downers Grove, IL). Endotoxin levels were de-
termined using a kit from Lonza (Basel, Switzerland). Antibodies for β-
actin (#12620), monocyte chemoattractant protein-1 (MCP-1)
(#2029), TNFα (#119487), phospho (Ser536) p65 (#3033), p65
(#3987), phospho (Thr172) AMPKα (#2535), AMPKα (#5832),
phospho (Thr202/Tyr204) ERK (#4370), and ERK (#9102) were ob-
tained from Cell Signaling Technology (Danvers, MA,). Antibodies for
F4/80 (sc-25830), heterogeneous nuclear ribonucleoprotein (hnRNP)
(sc-32301), HSC-70 (SC-1059), nitric oxide synthase 2 (NOS2) (sc-649),
and NOX4 (sc-21860) were from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Antibodies for ZO-1 (33-9100), occludin (71-1500), and
claudin-1 (71-7800) were from Invitrogen (Carlsbad, CA). Antibodies
for 4-hydroxinonenal (HNE) (ab46545) and NOX1 (ab55831) were
from Abcam Inc. (Cambridge, MA). PVDF membranes were obtained
from BIO-RAD (Hercules, CA, USA). The Enhanced chemiluminescence
(ECL) Western blotting system was from Thermo Fisher Scientific Inc.
(Piscataway, NJ). Apocynin, VAS-2780, EC, fluorescein isothiocyanate
(FITC)-dextran (4 kDa) and all other chemicals were purchased from
Sigma-Aldrich Co (St. Louis, MO).
2.2. Animals and animal care
All procedures were in agreement with standards for the care of
laboratory animals as outlined in the NIH Guide for the Care and Use of
Laboratory Animals. All procedures were administered under the aus-
pices of the Animal Resource Services of the University of California,
Davis. Experimental protocols were approved before implementation
by the University of California, Davis Animal Use and Care
Administrative Advisory Committee.
Healthy male C57BL/6J mice (20–25 g) (9–10 mice/group) were
fed for 15 weeks either: A- a diet containing approximately 10% total
calories from fat (Control) (TD.06416, Harlan Laboratories, Madison,
WI), B- a diet containing approximately 60% total calories from fat
(lard) (HF) (TD.06414, Harlan Laboratories, Madison, WI), C- the
control diet supplemented with 20 mg EC/kg body weight (CE), and D-
the HFD supplemented with 2 (HFE2), 10 (HFE10) or 20 (HFE20) mg
EC/kg body weight. EC-containing diets were prepared every two
weeks to account for changes in body weight and food intake, and to
prevent potential EC degradation. All diets were stored at −20 °C until
use. The highest amount of EC supplemented has been found to im-
prove insulin resistance in rats fed high fructose levels [18] and in mice
fed a HFD [19]. In comparison to EC intake in human populations [23],
the highest EC amounts supplemented are relatively high. However,
they can be reached by supplementation or consumption of select EC-
rich fruits/vegetables and derivatives [13].
Body weight and food intake were measured weekly throughout the
study as previously described [19]. After 15 weeks on the dietary
treatments, mice were euthanized by cervical dislocation. Blood was
collected from the abdominal aorta into heparinized tubes, and plasma
collected after centrifugation at 3000g for 10 min at room temperature.
Tissues were dissected and flash frozen in liquid nitrogen and then
stored at −80 °C for further analysis.
2.3. Metabolic measurements
For insulin tolerance tests (ITT), mice were fasted for 4 h and in-
jected intraperitoneally with 1 U/kg body weight human insulin
(Novolin R U-100, Novo Nordisk Inc, Princeton NJ). Blood glucose
values were measured before and at 15, 30, 60 and 120 min post-in-
jection. For glucose tolerance tests (GTT), overnight fasted mice were
injected with D-glucose (2 g/kg body weight), and blood glucose was
measured before and at 15, 30, 60, and 120 min post-injection. For both
tests glucose levels were measured using a glucometer (Easy Plus II,
Home Aid Diagnostics Inc, Deerfield Beach, FL). Total cholesterol, tri-
glycerides, glucose, insulin, GLP-2 and endotoxin concentrations, and
alanine transaminase activity were determined following manufac-
turer's guidelines.
2.4. Intestinal permeability
Intestinal permeability was measured after 13 weeks on the diets as
described previously [24] with minor modifications. Mice were fasted
for 4 h then gavaged with fluorescein isothiocyanate FITC-dextran
4 kDa (200 mg/kg body weight). After 90 min, 100 μl of blood were
collected from the tip of the tail vein. The blood was kept in the dark
and centrifuged at 3000g for 10 min at room temperature, and the
serum collected. Serum aliquots (20 μl) and a standard curve of FITC-
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dextran were plated in 96-well plates and diluted to 200 μl with 0.9%
(w/v) NaCl. Fluorescence was measured using a microplate spectro-
fluorometer (Wallac 1420 VICTOR2™, PerkinElmer Life Science,
Waltman, USA) at λexc: 485 nm and λem: 520 nm.
2.5. Caco-2 cell culture and assessment of monolayer permeability
Caco-2 cells (at passages 3 through 15) were cultured as previously
described [25]. Briefly, cells were used 21 d after reaching confluence
to allow for differentiation into intestinal epithelial cells. All the ex-
periments were performed in serum- and phenol red-free MEM.
Monolayer permeability was assessed measuring the transepithelial
electrical resistance (TEER) and the paracellular transport of FITC-
dextran (4 kDa) as described [25]. Briefly, cells were grown on trans-
well inserts (12 mm, 0.4 µm pore polyester membranes) in 12-well
plates (0.3 × 106 cells/transwell), and monolayers were used when
TEER values were between 350–450 Ω cm2. TEER was measured using
a Millicell-ERS Resistance System (Millipore, Bedford, MA) and calcu-
lated as: TEER = (Rm – Ri) × A (Rm, transmembrane resistance; Ri,
intrinsic resistance of a cell-free media; A, membrane surface area in
cm2). For the experiments, Caco-2 cell monolayers were preincubated
for 24 h with interpheron-γ (10 ng/ml) to upregulate the TNFα re-
ceptor. Monolayers were then incubated in the presence of 1 µM EC or
apocynin added to the upper compartment and incubated for 30 min.
Subsequently, cells were incubated in the absence or the presence of
TNFα (5 ng/ml) added to the lower compartment, and cells were fur-
ther incubated for 6 h. For TEER assessment, incubation media were
removed from the upper and lower compartments, cells rinsed with
HBSS 1X, and the same solution was added to both compartments.
The paracellular transport of FITC-dextran was measured after the
6 h incubation by adding 100 μM FITC-dextran (final concentration) to
the upper compartment. After 3.5 h incubation, 100 μl of the medium in
the lower compartment were collected, diluted with 100 μl HBSS 1X,
and fluorescence was measured at λexc: 485 nm and λem: 520 nm.
2.6. Western blot analysis
Tissue and cell total homogenates and nuclear fractions were pre-
pared as previously described [18,21,26]. Aliquots of total homo-
genates or nuclear fractions containing 25–40 μg protein were dena-
tured with Laemmli buffer, separated by reducing 7.5–12.5%
polyacrylamide gel electrophoresis, and electroblotted onto PVDF
membranes. Membranes were blocked for 1 h in 5% (w/v) bovine
serum albumin and subsequently incubated in the presence of the
corresponding primary antibodies (1:500–1:1000 dilution) overnight at
4 °C. After incubation for 90 min at room temperature in the presence
of the corresponding secondary antibodies (HRP conjugated) (1:10,000
dilution) the conjugates were visualized by ECL system using a Phos-
phoimager 840 (Amersham Pharmacia Biotech. Inc., Piscataway, NJ).
2.7. Histological analyses
The liver was removed and samples fixed overnight in 4% (w/v)
neutralized paraformaldehyde buffer solution. Samples were subse-
quently washed twice in phosphate buffer saline solution, dehydrated,
and then embedded in paraffin for histological analysis. Sections with a
thickness of 5 µm were obtained from paraffin blocks and placed on
glass slides. Hematoxylin and eosin staining was performed following
standard procedures. Sections were examined using an Olympus BX51
microscope (Olympus America Inc., Center Valley, PA, USA). Hepatic
histological examination was performed using the histological scoring
system for NAFLD as described by Kleiner et al. [27]. Three randomly
selected fields per animal were assessed blindly by an independent
pathologist who did not know the identities of the study groups. All
liver specimens were analyzed using Pro Plus 5.1 software (Media Cy-
bernetics, Rockville, MD).
2.8. Immunohistochemistry
Ileum samples were dissected out, fixed in 4% (w/v) solution of
paraformaldehyde in PBS overnight, rinsed with PBS and stored in 70%
(v/v) ethanol. Samples were embedded in paraffin and 5 µm sections
were obtained. Once deparaffinized, sections were processed for an-
tigen retrieval by incubation in 10 mM sodium citrate buffer (pH 6.0)
containing 0.05% (v/v) Tween 20 at 95 °C for 10 min, washed twice
with 0.1% (v/v) Triton X-100 in 0.1 M PBS, blocked for 50 min in 10%
(v/v) donkey serum in 0.1% (v/v) Triton X-100 in 0.1 M PBS, and in-
cubated overnight at 4 °C with primary antibodies for occludin (1:200),
ZO-1 (1:100) or claudin-1 (1:200). Sections were washed in PBS and
incubated for 2 h at room temperature with Cy2- or Cy3-conjugated
donkey anti-mouse or anti-rabbit IgG (1:500) (Jackson
ImmunoResearch Co. Laboratories West Grove, PA). After im-
munostaining, cell nuclei were stained with Hoechst 33342 and sec-
tions were imaged using an Olympus FV 1000 laser scanning confocal
microscope (Olympus, Japan). Olympus Fluoview version 4.0 software
was used to merge images. Four slices per animal and four animals from
each group were analyzed. The integrated optical density was measured
using Image Pro Plus 5.1 software (Media Cybernetics, Rockville, MD)
and expressed per area. Three randomly selected fields were measured
per animal for each antibody and experimental condition.
2.9. Determination of NADPH oxidase activity
NADPH oxidase activity was measured using a lucigenin-enhanced
chemiluminescence assay in membrane fractions from differentiated
Caco-2 cells incubated in the absence or the presence of TNFα (5 ng/
ml). For the isolation of membrane fractions, cells were homogenized in
Krebs Buffer (20 mM HEPES, 119 mM NaCl, 4.7 mM KCl, 1 mM MgSO4,
0.4 mM NaH2PO4, 0.15 mM Na2HPO4 and 1.25 mM CaCl2) containing
1 mM PMSF, and Roche proteases inhibitor cocktail (Roche,
Switzerland) and centrifuged at 800g for 10 min at 4 °C. The super-
natant was subsequently centrifuged at 100,000g for 60 min at 4 °C, the
pellet was collected (membrane fraction) and resuspended in Krebs
buffer. Aliquots of membrane fractions (30 μg of protein) were added
with or without 1 μM epicatechin or apocynin, and subsequently with
5 μM lucigenin and 50 μM NADPH. The reaction was followed under
temperature-controlled conditions (37 °C). Light emission was mea-
sured every 30 s for 20 min using a Biotek Synergy H1 plate reader
(BioTek Instruments, Inc.,Winooski, VT, USA) in the chemilumines-
cence mode. Results were expressed as the difference between the areas
under the curve in the absence and in the presence of the NADPH
oxidase inhibitor VAS-2780 (1 μM).
2.10. Microbiota analysis
Cecum content samples were collected in sterile tubes for sub-
sequent investigation of the microbiome through high throughput se-
quencing. Samples were stored at −80 °C until processing for DNA
extraction. Genomic DNA was extracted from cecal samples using the
Zymo Research Fecal DNA Miniprep Kit per the manufacturer's in-
structions (Zymo Research, Irvine, CA, USA). The V4 region of the 16S
rRNA gene was amplified by targeted barcoded primers F515 (5′-NNN
NNNNNGTGTGCCAGCMGCCGCGGTAA-3′) and R806 (5′-
GGACTACHVGGGTWTCTAAT-3′) as previously described [28]. Am-
plicons were then pooled and purified with the QIAquick PCR Pur-
ification Kit (Qiagen, Germantown, MD, USA) and taken to the UC
Davis Genome Center DNA Technologies Sequencing Core for library
preparation and paired-end sequenced on an Illumina Miseq. PEAR
[29] was used to merge the paired end reads and they were subse-
quently demultiplexed using the FASTX Toolkit (http://hannonlab.cshl.
edu/fastx_toolkit/). Cutadapt was then used to trim off barcodes and
primers from reads [30]. Read quality filtering, OTU picking using the
implemented swarm method, filtering the OTU table, rarefaction, and
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beta diversity data analysis was carried out within the QIIME software
package (University of Colorado, Boulder, CO, USA. version 1.9.1) [31].
Swarm was used within the QIIME package as the operational taxo-
nomic unit clustering method [32]. Beta diversity metrics were calcu-
lated based on Unifrac distances.
2.11. Statistical analysis
Data were analyzed by one-way analysis of variance (ANOVA) using
Statview 5.0 (SAS Institute Inc., Cary, NC). Fisher least significance
difference test was used to examine differences between group means.
A P value< 0.05 was considered statistically significant. Data are
shown as mean± SE.
3. Results
3.1. EC supplementation improves insulin sensitivity and dyslipidemia in
HFD-fed mice
As previously observed [19], consumption of a HFD for 15 weeks
caused obesity, dyslipidemia and insulin resistance in C57BL/6J mice
(Table 1). Body weight of HFD-fed mice was 40% higher than controls
(C and CE), and comparable to the three HFD-fed and EC-supplemented
groups. Plasma cholesterol and triglyceride levels were 43% and 63%
higher, respectively, in the HF group compared to controls, and both
were decreased only in the HFE10 and HFE20 groups.
Dietary EC supplementation (2–20 mg/kg body weight) attenuated
the hyperglycemia and hyperinsulinemia caused by HFD consumption
(Table 1). Chronic consumption of HFD was associated with decreased
insulin sensitivity and decreased glucose tolerance as evidenced by
Table 1
Metabolic parameters.
Parameter C CE HF HFE2 HFE10 HFE20
Body weight (g) 31.6±0.9a 33.0± 0.7a 44.0±1.6b 40.9± 2.2b 42.1± 2.6b 39.8± 1.9b
Food intake (g/d) 3.5± 0.19a 4.1± 0.05b 2.8± 0.17c 3.0± 0.07c 2.8± 0.09c 2.8±0.12c
Fasted glucose (mg/dl) 96±4a 85±12a 161±8b 134±9c 137±15b,c 130±7c
Fasted insulin (ng/ml) 0.15±0.04a 0.22± 0.10a 0.87±0.23b 0.38± 0.11a 0.47± 0.09a 0.37± 0.07a
Total cholesterol (mg/dl) 119± 6a 128±5a,d 170± 6b 156±10b,c 146±7c,d 136±10a,c
TG (mg/dl) 45.4±2.1a 55.4± 3.8c,d 73.8±3.6b 62.5± 3.2c 49.9± 3.2a,d 62.7± 1.3c
Results are shown as means± SE and are the average of 5-8 animals/group. Values having different superscripts are significantly different; (p<0.05, one way ANOVA).
Fig. 1. Effects of EC supplementation on metabolic parameters in HFD-fed mice. A- ITT and B- GTT (the corresponding area under the curve (A.U.C) is shown in the right panels), were
performed on weeks 9 and 11 on the diets, respectively. Mice were fed a control diet (empty circles and empty bars), the control diet supplemented with 20 mg EC/kg body weight (blue
circles and dashed bars), a HFD (HF) (black triangles and bars), or the HFD supplemented with 2 (HFE2), 10 (HFE10), or 20 (HFE20) mg EC/kg body weight (grey triangles and bars).
Results are shown as means± SE and are the average of 5–8 animals/group. Values having different symbols are significantly different (p< 0.05, one way ANOVA).
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insulin (ITT) and glucose (GTT) tolerance tests, respectively (Fig. 1A
and B). The area under the curve for the ITT in HF mice was 31% and
71% higher, and for the GTT, 54% and 73% higher, respectively, than
in C and CE groups. The ITT area under the curve was similar in the
HFE2, and significantly lower (26% and 44%, respectively) in the
HFE10 and HFE20 compared to the C group. At all concentrations
tested, EC supplementation mitigated HFD-mediated increase in the
GTT area under the curve. The above results confirm the capacity of
dietary EC to improve insulin sensitivity in HFD-fed C57BL/6J mice
even at the lowest concentration tested (2 mg/kg body weight). How-
ever, although most of the protective effects were observed in all the
range of concentrations assessed (2–20 mg/kg body weight), the
Fig. 2. Effects of EC supplementation on steatosis and hepatic inflammation. Mice were fed a control diet (empty bars), the control diet supplemented with 20 mg EC/kg body weight
(dashed bars), a HFD (HF) (black bars), or the HFD supplemented with 2 (HFE2), 10 (HFE10), or 20 (HFE20) mg EC/kg body weight (grey bars). On week 15 on the corresponding diets
the following parameters were measured: A-liver triglyceride content, B- plasma alanine amino transferase (ALT) activity, C- fat liver deposition and NAFLD activity score (NAS)
evaluated by hematoxylin/eosin tissue staining, D-proteins involved in inflammation: MCP-1, TNFα, NOS2 and F4/80 protein levels were measured by Western blot. Bands were
quantified and values referred to β-actin levels (loading control). Results for HF, HFE20 and CE were referred to control group values (C). Results are shown as mean± SE of 5–8 animals/
group. A,B- Values having different symbols are significantly different; C,D- #Significantly different from all other groups; (p< 0.05, one way ANOVA test).
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highest EC concentration was that consistently effective in all the dif-
ferent parameters tested. Thus, in most of the following experiments we
have evaluated select parameters only in the groups supplemented with
20 mg/kg body weight (CE, HFE20).
3.2. EC supplementation attenuates HFD-induced steatosis and
inflammation
The effects of EC on liver steatosis and inflammation triggered by
the consumption of a HFD were assessed by measuring liver triglyceride
content using a biochemical assay, inflammation markers by Western
blot, and histology. Liver triglyceride content was 38% higher in HF
mice. Values for EC-supplemented mice were similar to controls
(Fig. 2A). Accordingly, hematoxylin-eosin stained liver sections showed
higher NAFLD activity score in liver from HF mice compared to C, CE
and HFE20 mice (Fig. 2C). Although not statistically different, the CE
group showed a trend (p<0.07) for higher NAFLD activity score than
the C group. Steatosis-associated cell damage was also evaluated by
measuring plasma alanine aminotransferase (ALT) activity in plasma. In
HF mice we observed 48% and 68% higher activity of plasma ALT
compared to the C and CE groups (Fig. 2B). Supplementation with
20 mg EC/kg body weight prevented this increase. Values for HFE2 and
HFE20 mice were not significantly different to those of controls and HF.
We next evaluated the capacity of EC to mitigate HFD-induced liver
inflammation by measuring hepatic protein levels of the chemokine
MCP-1, the cytokine TNFα, NOS2, and the macrophage marker F4/80
by Western blot. In HF mice we observed 81%, 210%, 40% and 58%
higher levels of MCP-1, TNFα, NOS2 and F4/80, respectively, compared
to the C group. Supplementation with EC (HFE20) mitigated the effects
of the high fat feeding on the expression of all the tested proteins
(Fig. 2D).
3.3. EC supplementation prevents intestinal permeabilization and
endotoxemia in HFD-fed mice
Increased intestinal permeability and the associated increase in
bacterial endotoxins in the bloodstream are significant contributors to
HFD- and obesity-associated steatosis. Thus, we investigated the effects
of EC supplementation on HF-induced permeabilization and increased
plasma endotoxin levels. We measured intestinal permeability using
FITC-dextran after 13 weeks on the corresponding diets. The intestinal
paracellular permeability to FITC-dextran was 100% higher in the HF
group compared to controls and all the EC-supplemented groups
(Fig. 3A). Plasma endotoxin levels were 63% higher in HF mice than in
controls. EC supplementation either partially (HFE10) or significantly
(HFE20) mitigated endotoxemia (Fig. 3B). Plasma endotoxin levels
positively correlated with plasma ALT activity (r: 0.84, p = 0.04), and
with the area under the curve corresponding to the GTT (r: 0.89, p =
0.02).
Fig. 3. Effects of EC on epithelial barrier permeabilization induced by HFD consumption in mice and by TNFα in Caco-2 cells. A,C- Mice were fed a control diet (empty bars), the control
diet supplemented with 20 mg EC/kg body weight (dashed bars), a HFD (HF) (black bars), or the HFD supplemented with 2 (HFE2), 10 (HFE10), or 20 (HFE20) mg EC/kg body weight
(grey bars). Intestinal permeability was evaluated by measuring at week 13 FITC-dextran permeability (A), and at week 15 plasma endotoxin (B) and TNFα (C) concentrations. Results are
shown as mean±SE of 5–8 animals/group. D- FITC-dextran transport and D- TEER in Caco-2 cells. Polarized cells were incubated for 6 h at 37 °C in the absence of additions (control, C);
or after addition of 5 ng/ml TNFα to the lower chamber in the absence (TNF) or the presence of 1 μM EC or 1 μM apocynin (Apo) added to the upper chamber. Results are shown as
mean± SE of 3 independent experiments. A,C-E- #Significantly different from all other groups; B-Values having different symbols are significantly different; (p< 0.05,one way ANOVA
test).
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3.4. EC prevents TNFα-induced permeabilization of Caco-2 cell monolayers
TNFα is a major inducer of intestinal barrier permeabilization.
TNFα plasma concentration was 2.3-fold higher in HF mice compared
to controls, and EC supplementation caused only a partial prevention
(47%) of this increase (Fig. 3C). Thus, using Caco-2 monolayers as an in
vitro model of intestinal barrier, we further assessed the capacity of EC
to protect the monolayer from TNFα-induced permeabilization. For this
purpose, we measured the FITC-dextran paracellular transport and the
monolayer transepithelial electrical resistance (TEER). TNFα (5 ng/ml),
added to the lower chamber, caused a 1.1-fold increase in FITC-dextran
transport (Fig. 3D) and a 31% decrease in TEER (Fig. 3E) in Caco-2 cell
monolayers. These changes were prevented by simultaneous incubation
of cells with EC (1 μM) or with apocynin (1 μM) added to the upper
chamber.
3.5. EC supplementation attenuates HFD-induced alterations in TJ protein
expression
An increased intestinal permeability can be due to impaired TJ
structure and/or function. To investigate the potential protective effects
of EC on HFD-mediated alterations of TJs, we examined the expression
of the TJ proteins ZO-1, occludin, and claudin-1 in mouse ileum by
Western blot and by immunofluorescence. ZO-1, occludin and claudin-1
protein levels assessed by Western blot were 64%, 55% and 33% lower,
respectively, in the ileum from HF mice compared to controls (Fig. 4A).
Supplementation of the HF mice with 20 mg EC/kg body weight pre-
vented the decrease in ZO-1, occludin and claudin-1. Similar trends
were observed when TJ proteins were evaluated by immuno-
fluorescence confocal microscopy (Fig. 4B and C).
3.6. Mechanisms underlying the protective effects of EC on HFD-induced
increased intestinal permeability
Intestinal permeability can be regulated by different cell signaling
pathways (ERK1/2, AMPK and NF-κB), some of which are susceptible to
redox regulation. GLP-2 is a major regulator of epithelial monolayer
permeability. To assess signaling activation we measured the phos-
phorylation of ERK1/2, NF-κB (p65) and AMPK, and the nuclear pre-
sence of p65 by Western blot (Fig. 5A and B). Higher levels of ERK1/2,
p65, and AMPK phosphorylation were observed in HF, but not in HFE20
mice when compared to controls (Fig. 5A). In agreement with the
pattern of p65 phosphorylation in total homogenates, nuclear p65 le-
vels were significantly higher (98%) in the HF group compared to
controls and HFE20 mice (Fig. 5B). Plasma GLP-2 levels were 1- and
1.5-fold higher in CE and HFE20 mice, respectively, compared to the C
group (Fig. 5C). In HF mice, plasma GLP-2 concentration was not sta-
tistically different compared to the control groups. Significantly, plasma
GLP-2 levels in both EC-supplemented groups (CE, HFE20) were sig-
nificantly higher than in control mice.
Oxidative stress could contribute to intestinal permeabilization
upon HFD consumption. Thus, we measured protein levels of ileum
Fig. 4. Effects of EC supplementation on HFD-induced alterations in ileum tight junction protein expression. Mice were fed a control diet (empty bars), the control diet supplemented with
20 mg EC/kg body weight (dashed bars), a HFD (HF) (black bars), or the HFD supplemented with 20 mg (HFE20) EC/kg body weight (grey bars). A- TJ proteins occludin, claudin-1 and
ZO-1, expression was measured by Western blot. Bands were quantified and values referred to HSC70 levels (loading control). Results for HF, HFE20 and CE were referred to control
group values (C). Results are shown as mean±SE of 8 animals/treatment. B- Representative images for immunohistochemistry and confocal microscopy for occludin and ZO-1 (red
fluorescence), and claudin-1 (green fluorescence). Hoechst was used for nuclear counterstaining (blue). Bar: 50 µm C- Fluorescence intensity was measured as described in methods and
results are shown as mean± SE of 4 animals/treatment. A,C- #Significantly different from all other groups; (p< 0.05, one way ANOVA test).
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NADPH oxidases NOX1 and NOX4, and 4-hydroxynonenal (HNE)-pro-
tein adducts as parameter of oxidative stress (Fig. 6A). NOX4 and NOX1
levels were 50% higher in the ileum from HF mice than in controls, and
this was prevented by EC supplementation (Fig. 6B). 4-HNE-protein
adducts in the molecular weight corresponding to actin were 24%
higher in HF mice than in all other groups. To assess the potential in-
volvement of NADPH oxidases on intestinal permeabilization, we
measured the effects of TNFα, EC, and apocynin on the expression of
NOX1 and NOX4, and on NADPH oxidase activity in Caco-2 cells. TNFα
caused a 79% and 52% increase in NOX1 and NOX4 expression, re-
spectively (Fig. 6B). Both EC and apocynin (1 μM) prevented both in-
creases. Supporting a condition of increased oxidant production and
oxidative stress, TNFα caused higher (38%) levels of 4-HNE-protein
adducts in Caco-2 cells, which were prevented by EC and apocynin. At
1 μM concentration, both EC and apocynin added to Caco-2 membrane
fractions inhibited NADPH oxidase activity (Fig. 6C). The above ex-
periments support the capacity of EC to inhibit NADPH oxidase both at
the level of expression and activity.
3.7. EC supplementation does not affect HFD-induced dysbiosis
As expected, the chronic consumption of a HFD caused dysbiosis in
mice. Principal component analysis of cecum microbiota showed
clearly separated clusters for the control and HF groups. EC supple-
mentation did not normalize the observed microbiota cluster segrega-
tion (Fig. 7).
4. Discussion
This study presents evidence that EC supplementation mitigates
intestinal permeabilization and endotoxemia induced by HFD con-
sumption in mice. EC protected the integrity of the TJ and modulated
signaling pathways that contribute to TJ normal function, including
NOX1/NOX4 upregulation, oxidative stress, and NF-κB and ERK1/2
activation. The involvement of NADPH oxidase in EC-mediated pro-
tection of barrier integrity in HFD-fed mice was supported by evidence
in Caco-2 cells. The beneficial effects of EC supplementation on in-
testinal permeability could protect the liver from endotoxin-induced
damage. This may explain EC capacity to improve the metabolic profile
in HFD-induced obesity and T2D [19,20].
The link between steatosis and a “leaky gut” is supported by a large
body of evidence associating NAFLD to different conditions with in-
creased intestinal permeability, including cardiometabolic disorders,
obesity [2,3], and inflammatory bowel diseases [33]. We currently
Fig. 5. Effects of EC supplementation on HFD-induced alterations on signaling events that regulate intestinal permeability. Mice were fed a control diet (empty bars), the control diet
supplemented with 20 mg EC/kg body weight (dashed bars), a HFD (HF) (black bars), or the HFD supplemented with 20 mg EC/kg body weight (HFE20) (grey bars). A- Phosphorylation
levels of ERK1/2 (Thr202/Tyr204), p65 (Ser536) and AMPK (Thr172) in total ileum homogenates, and B- p65 and hnRNP levels in ileum nuclear fractions were measured by Western
blot. Bands were quantified and values referred to either (A) the non-phosphorylated protein form or (B) hnRNP levels. Results for HF, HFE20 and CE were referred to control group
values (C). C- Plasma GLP-2 concentration was measured using a commercial kit. A-C- Results are shown as mean± SE of 6–8 animals/treatment. A,B- #Significantly different from all
other groups; C- Values having different symbols are significantly different; (p<0.05, one way ANOVA test).
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observed that the chronic consumption of a HFD led to steatosis, liver
inflammation (high tissue chemokines and cytokines, NOS2, and mac-
rophage F4/80 protein levels) and damage (high ALT plasma activity)
in mice. This can in part explain previous findings showing impaired
hepatic response to insulin in HFD mice [19]. EC improved systemic
glucose homeostasis, and mitigated HFD-induced liver triglyceride ac-
cumulation, inflammation and ALT release. Accordingly, in a rat model
of high fructose-induced T2D, EC supplementation also prevented he-
patic triglyceride accumulation and insulin resistance [18]. Over-
feeding is recognized as a contributor of NAFLD [34]. Although EC can
prevent steatosis in two models of overfeeding (high fat and high
fructose diets) in mice, the underlying mechanisms are unknown. Evi-
dence that EC can preserve Caco-2 cell monolayer permeability in an in
vitro model of inflammation [22], points to the intestinal barrier as a
potential target of EC beneficial actions on steatosis, and hepatic/sys-
temic insulin resistance.
A permeable intestinal epithelium allows the paracellular transport
of bacterial and dietary antigens leading to local and systemic in-
flammation [5,7]. For example, endotoxemia occurs upon overfeeding
in men [35], as a consequence of consuming a HFD in T2D patients
Fig. 6. Effects of EC on the upregulation of intestinal NADPH oxidases and protein oxidation induced by HFD consumption in mice and by TNFα in Caco-2 cells. Total protein levels of
NOX4, NOX1, and HNE-protein adducts (MW: 40 kDa) were measured by Western blot in: A- the ileum of mice fed a control diet (empty bars), the control diet supplemented with 20 mg
EC/kg body weight (dashed bars), a HFD (HF) (black bars), or the HFD supplemented with 20 mg EC/kg body weight (HFE20) (grey bars); B- Caco-2 cells incubated for 6 h at 37 °C in the
absence of additions (control, C) (empty bars); or after addition of 5 ng/ml TNFα in the absence (TNF) (dark blue bars) or the presence of 1 μM EC (TNF + EC) (light blue bars) or 1 μM
apocynin (Apo) (grey bars). Bands were quantified and values referred to β-actin or HSC70 levels (loading controls). Results were referred to control group values (C). C- In vitro effects of
1 μM EC and apocynin (Apo) on NADPH oxidase activity were measured in membrane fractions isolated from Caco-2 cells incubated without or with 5 ng/ml TNFα for 6 h. Results are
shown as mean±SE of A- 6–8 animals/treatment, and B,C- 4 independent experiments. #Significantly different from all other groups (p< 0.05, one way ANOVA test).
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[36], and correlates with energy intake in healthy individuals [37]. One
consequence of increased endotoxemia is liver inflammation, steatosis
and insulin resistance. In support of this mechanism, all these symp-
toms manifest in mice i.p. injected with LPS for four weeks [5]. We
observed that EC prevented HFD-induced barrier permeabilization and
increased circulating endotoxin. Accordingly, an EC-containing cocoa
extract decreased endotoxemia in high fat fed mice [38]. Suggesting a
potential link between a leaky gut and liver dysfunction upon HFD
consumption, we observed that plasma endotoxin concentrations posi-
tively correlated with plasma ALT activity (parameter of liver damage),
and GTT area under the curve (parameter of glucose tolerance).
The protective capacity of EC on intestinal permeability is in part
due to the preservation of TJ structure. HFD consumption caused a
decreased expression of the TJ proteins occludin, claudin-1 and ZO-1 in
the ileum, which was prevented by EC supplementation. Among several
factors, TNFα is a central trigger of TJ structural/functional disruption.
EC partially mitigated HFD-induced increase in circulating TNFα which
can partially explain the protective action of EC on barrier function.
This is in agreement with previous observations showing that EC pro-
tects Caco-2 monolayers from TNFα-induced decrease in ZO-1 expres-
sion, alteres ZO-1 subcellular distribution, and increases paracellular
transport [22]. NADPH oxidase is activated when TNFα binds to its
receptor, and increased O2.- production contributes to TNFα-induced TJ
disruption [22]. EC mitigated HFD-induced increased expression of
NOX1 and NOX4 and protein oxidation in the ileum. Significantly, we
also observed that the permeabilization of Caco-2 monolayers by TNFα
was associated with increased NOX1 and NOX4 expression and protein
oxidation. As previously observed in other tissues [18,20,39,40], EC
mitigated NADPH oxidase overexpression (NOX1 and NOX4) in HFD-
fed mice and Caco-2 cells, and inhibited the enzyme activity in cells. In
vitro experiments showing the parallel action of a NADPH oxidase in-
hibitor (apocynin) and EC preventing TNFα-induced permeabilization
and NADPH oxidase overexpression and activity, strongly support
ileum epithelial NADPH oxidase as a significant target for the protective
actions of EC on HFD-induced intestinal barrier permeabilization in
mice. Both NOX1 and NOX4 have κB sites in their promoters, and NF-κB
is a central regulator of both NOX1 and NOX4 expression [41]. Thus, a
decrease in cellular O2.- /H2O2 production as a consequence of NADPH
oxidase inhibition, and subsequent inhibition of NF-κB activation, can
explain the observed prevention by EC and apocynin of HFD- and
TNFα-induced overexpression of both NOX1 and NOX4. On the other
hand, it has been argued that apocynin is not a NADPH oxidase in-
hibitor unless the dimer is formed. However, apocynin inhibits NADPH
oxidase in vitro both as monomer and as dimer, with an IC50 4-fold
lower for the dimer than for the monomer [40]. The low (1 μM) con-
centration of apocynin that inhibited TNFα-induced Caco-2 monolayer
permeabilization suggests that the involved mechanism is primarily the
inhibition of NADPH oxidase rather than a direct antioxidant action.
Overall, although the role of NADPH oxidase on TJ structure/function
regulation is not completely understood, an increase in O2.-/H2O2
production could increase intestinal permeability through the oxidation
of TJ structural and modulatory proteins and, as described below, the
activation of select redox-sensitive signals.
Different signaling cascades are involved in the regulation of TJ
assembly. AMPK plays a key role in promoting the assembly of TJs
[42,43]. On the other hand, AMPK is also important for nutrient ab-
sorption [44]. In our model, AMPK activation by HFD consumption
seems to be related to the local management of nutrient absorption and
metabolism rather than to the regulation of intestinal permeabilization.
Very importantly, TNFα activates pathways that increase TJ perme-
ability, including NF-κB and ERK1/2. NF-κB regulates the transcription
of myosin light chain kinase (MLCK) [45,46], which increases TJ per-
meability by phosphorylating the myosin light chain protein. ERK1/2
activation increases TJ permeability by regulating the expression of TJ
proteins [47] and promoting MLCK transcription via the ETS domain-
containing protein ELK-1 [48]. Thus, the above results are consistent
with an upstream regulatory effect of EC (i.e. TNFα-triggered NADPH
oxidase activation) in the inhibition of NF-κB and ERK1/2 activation
and ultimately TJ disruption.
Different factors/events are proposed to contribute to the intestinal
permeabilization triggered by HFD consumption including fat per se, an
increase in luminal bile acids, and alterations in the microbiota [49]. In
fact, consumption of HFDs with different fat sources leads to increased
intestinal permeability in mice [50]. Dysbiosis, including increased
Bacteroides and decreased Firmicutes, decreased bacterial diversity and
altered representation of bacterial genes, is observed in obese in-
dividuals [51,52]. Consumption of high energy foods, obesity and
dysbiosis are linked to steatosis and NAFLD [24,53–55]. Although the
microbiota can be central to energy metabolism, intestinal perme-
ability, endotoxemia and steatosis; mitigation of dysbiosis by EC
through changes in microbiota composition does not seem to be the
mechanism involved in the observed EC beneficial effects. This is based
on the lack of effects of EC on the overall microbiota changes observed
as a consequence of HFD consumption.
GLP-2 is a 33 aminoacid peptide that is generated from the cleavage
of proglucagon. GLP-2 is involved in different aspects of intestinal
physiology, including trophic actions and decreased barrier paracellular
transport [56]. GLP-2 also protects the liver from steatosis. In this re-
gard, mice fed a HFD and injected with an antagonist to the GLP-2
receptor showed worsening of triglyceride hepatic deposition and
steatosis degeneration [57]. EC supplementation increased plasma GLP-
2 levels both in control and HFD-fed mice. Thus, EC-mediated plasma
GLP-2 increase could contribute to the mitigation of steatosis by both
preserving the structure/function of TJs in HF mice, and also decreasing
hepatic triglyceride deposition.
In summary, consumption of a HFD leads to intestinal permeabili-
zation, steatosis, hepatic inflammation and insulin resistance in mice.
EC supplementation mitigates all these adverse effects. HFD-induced
endotoxemia, secondary to increased intestinal permeabilization can be
in part involved in the development of steatosis. Indeed, HFD con-
sumption caused alterations in TJ composition, and affected events
involved in intestinal permeabilization, including dysbiosis and in-
creased plasma TNFα. In the ileum, HFD consumption triggered a
cascade of redox-related events: upregulation of NOX1/NOX4, protein
oxidation, activation of NF-κB and ERK1/2, and TJ disruption. EC
protection of barrier function is in part due to its capacity to preserve
normal TJ composition in part by preventing NOX1/NOX4 upregula-
tion, inhibiting NF-κB and ERK1/2, and increasing GLP-2 expression.
Current results support the concept that dietary EC might be important
in mitigating the adverse effects of Western style diets.
Fig. 7. Effects of EC on HFD-induced changes in cecal microbiota. Changes in cecal mi-
crobiota assessed by clustering of samples based on diet. Principal coordinate analysis
(PCA) was performed based on the weighted UniFrac distance matrix generated from
sequencing fecal 16S rRNA gene in cecum samples from mice fed the corresponding diets
for 15 weeks. The X-axis represents the tertiary coordinate, the Y-axis represents the
secondary coordinate. Axis numbering represents the relative distance between samples
based on the weighted UniFrac distance matrix.
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